Cable Hill Partners’s Allena Pharmaceuticals ALNA Stock Holding History

Cable Hill Partners’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,000	Closed	-$13K	–	98
2020 Q1	$13K	Buy	+13,000	New	+$26K	﹤0.01%	88
2018 Q3	–	Sell	-500	Closed	-$7K	–	904
2018 Q2	$7K	Sell	500 -500	-50%	-$7.21K	﹤0.01%	578
2018 Q1	$13K	Buy	+1,000	New	+$8.35K	0.01%	429

Other funds holding ALNA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Cable Hill Partners's ALNA Position: Q2 2020 in Review

Cable Hill Partners sold out of Allena Pharmaceuticals (ALNA) in Q2 2020, closing a stake of 13,000 shares — an estimated $13K sold.

Cable Hill Partners first reported a position in ALNA in Q1 2018 and held it in 3 quarters. The position peaked at $13K in Q1 2020. 30 funds tracked by Wall St. Rank hold ALNA as of Q2 2020.

Cable Hill Partners reported no remaining Allena Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Cable Hill Partners sold 13,000 Allena Pharmaceuticals shares in Q2 2020, an estimated $13K.
Cable Hill Partners first reported a position in Allena Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Cable Hill Partners's Allena Pharmaceuticals position peaked at $13K in Q1 2020.
30 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2020.

Based on Cable Hill Partners's 13F filing for Q2 2020, filed 13 Aug 2020.